IDRA with ~100MC will Explode Soon.. | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1674 of 1704  at  11/10/2020 3:07:05 PM  by

cert77


IDRA with ~100MC will Explode Soon..

 Mystery solved. Received the confirmation from the lead investigator of the new trial ( Metastatic Pancreatic Cancer) that they will be using IMO-2125 from IDRA.If any question, please email to the team and confirm. (see the email received attached). Currently under the hood IDRA has started IMO-2125 in many more indications besides RR melanoma. So far, four solid tumors trials running besides the Phase-3 RR melanoma data which is expected in < four months and still the MC is ~100 MC..Strange ..isn't it ???

 

RR Melanoma**Ph-3 data with ~450 patients in <4 months**

 MSS CRC

Head & Neck

Pancreatic **New Trial, started recruitment as well **

1)A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (ILLUMINATE-301)

https://clinicaltrials.gov/ct2/show/NCT03445533?term=idera+pharmaceuticals&draw=2&rank=4

2) Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

https://clinicaltrials.gov/ct2/show/NCT03865082?term=Tilsotolimod&draw=2&rank=1

3)A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

https://clinicaltrials.gov/ct2/show/NCT04196283?term=Tilsotolimod&draw=2&rank=2

4)A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor

Stage (p) T3-4 cN0M0 Melanoma (INTRIM)

https://clinicaltrials.gov/ct2/show/NCT04126876?term=Tilsotolimod&draw=2&rank=3

5)Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and

Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO)

https://clinicaltrials.gov/ct2/show/NCT04270864?term=Tilsotolimod&draw=2&rank=4

6)PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer ***NEW TRIAL***

https://clinicaltrials.gov/ct2/show/NCT04612530?cond=NCT04612530&draw=2&rank=1

Below is the Email Confirmation Received for the new trial:
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...